3. BCL-2 as a therapeutic target in chronic lymphocytic leukemia. Daniel C; Mato AR Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276 [TBL] [Abstract][Full Text] [Related]
4. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Int J Hematol; ; . PubMed ID: 33094474 [TBL] [Abstract][Full Text] [Related]